Results 31 to 40 of about 15,919 (234)

Baseline clinical characteristics according to DOAC type.

, 2023
Baseline clinical characteristics according to DOAC type.
René Acosta-Isaac (14241647), Mariana Corrochano (14241644), Carla Moret (14241653), Blanca Jiménez (14675376), Juan Carlos Souto (9283172), Melania Plaza (14241650), Sergi Mojal (398676)   +6 more
core   +1 more source

Effect of previous INR control during VKA therapy on subsequent DOAC adherence and persistence, in patients switched from VKA to DOAC

, 2023
Introduction  Current guideline suggests a switch from vitamin K antagonist (VKA) to direct oral anticoagulant (DOAC) in patients with low time in therapeutic range (TTR 
Tichelaar, Vladimir, Tichelaar, Vladimir Y. I. G., Elling, Tessa, Veeger, Nic J. G. M., Meijer, Karina; id_orcid, Jens H.J. Bos, Bos, Jens H., Vladimir Tichelaar, Eelko Hak, Tessa Elling, Bos, Jens H J; id_orcid, Karina Meijer, Hak, Eelko, Meijer, Karina, Veeger, Nic J G M; id_orcid, Nic J.G.M. Veeger   +15 more
core   +1 more source

Evaluation of the Determination of Dabigatran, Rivaroxaban, and Apixaban in Lupus Anticoagulant-Positive Patients

Diagnostics, 2021
Background: The effect of direct oral anticoagulants (DOAC) on laboratory tests dependent on the production of their targets, factor IIa and factor Xa, is a well-known problem and can cause both false positive and negative results.
Jana Úlehlová, Barbora Piskláková, Eliška Ivanovová, Jana Procházková, Pavla Bradáčová, Aleš Kvasnička, David Friedecký, Luděk Slavík   +7 more
doaj   +1 more source

Venous thromboembolic complications in lymphoma patients [PDF]

Medicinski Podmladak, 2020
Lymphomas represent a heterogeneous group of malignant hematological diseases with high risk for development of venous thromboembolic complications (VTE). Consequently, VTE significantly impacts morbidity and mortality in these patients.
Otašević Vladimir, Antić Darko, Mihaljević Biljana   +2 more
doaj   +1 more source

DOAC‐Stop in lupus anticoagulant testing: Direct oral anticoagulant interference removed in most samples

Research and Practice in Thrombosis and Haemostasis, 2021
Background The use of direct oral anticoagulants (DOACs) is a convenient therapeutic option for patients at risk of thrombosis. DOACs interfere with clot‐based testing for the identification of lupus anticoagulant antibodies (LACs) in patients with ...
Steven Andrew Baker, Jing Jin, Christopher Pfaffroth, Trang Vu, James L. Zehnder   +4 more
doaj   +1 more source

Characteristics of ICH with Warfarin and DOAC [PDF]

, 2018
Background: Direct oral coagulants (DOAC) have been shown to decrease the frequency of intracerebral hemorrhage (ICH) compared with warfarin. However, the precise characteristics, such as the size and locations of the hemorrhage, and outcome and onset ...
Kawabori, Masahito, Matsubara, Koji, Yoshimasa Niiya, Shoji Mabuchi, Ozaki, Hiroyuki, Mabuchi, Shoji, Motoyuki Iwasaki, Houkin, Kiyohiro, Iwasaki, Motoyuki, Hiroyuki Ozaki, Niiya, Yoshimasa, Masahito Kawabori, Koji Matsubara, Kiyohiro Houkin   +13 more
core   +1 more source

Direct oral anticoagulants increase bleeding risk after endoscopic sphincterotomy: a retrospective study

BMC Gastroenterology, 2021
Background Bleeding can be a serious adverse event of endoscopic sphincterotomy (EST). However, the risk of EST bleeding between direct oral anticoagulant (DOAC) users and those who received no antithrombotic agents has not been clarified.
Sakue Masuda, Kazuya Koizumi, Takashi Nishino, Tomohiko Tazawa, Karen Kimura, Junichi Tasaki, Chikamasa Ichita, Akiko Sasaki, Makoto Kako, Haruki Uojima, Ayumu Sugitani   +10 more
doaj   +1 more source

Mechanistic Basis for the Differential Effects of Rivaroxaban and Apixaban on Global Tests of Coagulation

TH Open, 2018
Rivaroxaban and apixaban are both small molecules that reversibly inhibit factor Xa. Compared with rivaroxaban, apixaban has minimal effects on the prothrombin time and activated partial thromboplastin time.
Paul Y. Kim, Calvin H. Yeh, Brian J. Dale, Beverly A. Leslie, Alan R. Stafford, James C. Fredenburgh, Jack Hirsh, Jeffrey I. Weitz   +7 more
doaj   +1 more source

Edoxaban, a Factor Xa-Specific Direct Oral Anticoagulant, Significantly Suppresses Tumor Growth in Colorectal Cancer Colon26-Inoculated BALB/c Mice

TH Open, 2023
Introduction Certain low-molecular-weight heparins have been reported to reduce tumor growth and metastasis in tumor cell-inoculated mouse models and cancer patients.
Keiichi Hiramoto, Nobuyuki Akita, Junji Nishioka, Koji Suzuki   +3 more
doaj   +1 more source

Impact of a commercially available DOAC absorbent on two integrated procedures for lupus anticoagulant detection

, 2021
Background: Lupus anticoagulant (LA)-detection in anticoagulated patients is an unmet need, which becomes even more cogent with the introduction of direct oral anticoagulants (DOAC) that may lead to false-positive results.
Boscolo-Anzoletti M., Peyvandi F., Chantarangkul V., Testa S., Scalambrino E., Paoletti O., Clerici M., Tripodi A., Novembrino C.   +8 more
core   +1 more source